SoftOx Solutions announced the signing of the final grant agreement for the COUNTERACT Consortium - which includes SoftOx - with the European Defence Fund. COUNTERACT aims to reinforce the European Union's preparedness for chemical, biological, radiological and nuclear (CBRN)-type threats. The project includes
pre-clinical and clinical studies on the safety and efficiency of medical countermeasures targeting CBRN-type threats. The project will cover a four-year period and started in December 2022. This project brings together key European players: from 11 EU Member states (five universities; three technological research bodies; ten public research institutes; eight SME and start-ups). 19 of these are related to the part of the project where SoftOx
is involved. SoftOx is a part of the COUNTERACT consortium, and the SoftOx technology is one of the three main technologies forming the basis for the grant. This funding of NOK 97 million related to the first of four possible
phases, will contribute to the development of an MCM inhalator based on the SoftOx technology. EDF communicates a willingness to continue giving support to technologies that deliver results in line with expectations. New calls will be announced on an annual basis through 2027.